Loss of lamivudine resistance in a zidovudine and lamivudine dual-resistant HIV-1 isolate after discontinuation of in vitro lamivudine drug pressure

Antiviral Therapy

Volumn 3, Issue 4, 1998, Pages 203-207

  Rusconi, Stefano ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE;

ARTICLE; CODON; DNA SEQUENCE; GENE EXPRESSION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; REVERTANT; VIRUS CULTURE;

ANTI-HIV AGENTS; CODON; DRUG RESISTANCE; GENOTYPE; HIV-1; HUMANS; LAMIVUDINE; PHENOTYPE; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; VIRUS REPLICATION; ZIDOVUDINE;

EID: 0032446133     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Coates JAV, Cammack N, Jenkinson HJ, Jowett AJ, Jowett MI, Pearson BA, Penn CR, Rouse PL, Viner KC & Cameron JM. (-)-2′-deoxy-3′-thiacytidine (lamivudine) is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrobial Agents and Chemotherapy 1992; 36:733-739.
2. Hart GJ, Orr DC, Penn CR, Figueiredo HT, Gray NM, Boehme RE & Cameron JM. Effect of (-)-2′-deoxy-3′-thiacytidine (lamivudine) 5′-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma. Antimicrobial Agents and Chemotherapy 1992; 36:1688-1694.
3. Bartlett JA, Benoit SL, Johnson VA, Quinn JB, Sepulveda GE, Ehmann WC, Tsoukas C, Fallon MA, Self PL & Rubin M. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. Annals of Internal Medicine 1996; 125:161-172.
4. Eron JJ, Benoit SH, Jemsek J, MacArthur RD, Santana J, Quinn JB, Kuritzkes DR, Fallon MA & Rubin M for the North American HIV Working Party. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. New England Journal of Medicine 1995; 333:1662-1669.
5. Katlama C, Ingrand D, Loveday C, Clumeck N, Mallolas J, Staszewski S, Johnson M, Hill AM, Pearce G, McDade H & Lamivudine European HIV Working Group. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-naive patients. A randomized controlled comparison with zidovudine monotherapy. Journal of the American Medical Association 1996; 276:118-125.
6. Kuritzkes DR, Quinn JB, Benoit SL, Shugarts DL, Griffin A, Bakhtiari M, Poticha D, Eron JJ, Fallon MA & Rubin M. Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS 1996; 10:975-981.
7. Staszewski S, Loveday C, Picazo JJ, Dellamonica P, Skinhoj P, Johnson MA, Danner SA, Harrigan PR, Hill AM, Verity L, McDade H & Lamivudine European HIV Working Group. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Journal of the American Medical Association 1996; 276:111-117.
8. CAESAR Coordinator Committee. Randomized trial of addition of lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997; 349:1413-1421.
9. Tisdale M, Kemp SD, Parry NR & Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proceedings of the National Academy of Sciences, USA 1993; 90:5653-5656.
10. Boucher CAB, Cammack N, Schipper P, Schuurman R, Rouse PL & Cameron JM. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents and Chemotherapy 1993; 37:2231-2234.
11. Goulden MG, Cammack N, Hopewell PL, Penn CR & Cameron JM. Selection in vitro of an HIV-1 variant resistant to both lamivudine (3TC) and zidovudine. AIDS 1996; 10:101-102.
12. Rusconi S, De Pasquale MP, Milazzo L, Bulgheroni E, Citterio P, Kurtagic S, d'Arminio-Monforte A & Galli M. In vitro effects of a continuous pressure with zidovudine (zidovudine) and lamivudine (3TC) on a zidovudine-resistant HIV-1 isolate. AIDS 1997; 11:1406-1410.